Hutchmed (00013.HK) announced that it will receive a milestone payment of 10 million USD from its partner Takeda (TAK.US). Takeda obtained FRUZAQLA in December of this year in Spain, for the treatment of previously treated metastatic colorectal cancer patients, which has been recommended for inclusion in public medical insurance coverage. This is the first recommendation for inclusion in public medical insurance coverage obtained in Europe.

The announcement states that FRUZAQLA received approval from the European Commission in June of this year. Takeda holds the global exclusive license for further development, commercialization, and production of furmonertinib outside of mainland China, Hong Kong, and Macau. (js/w)

~